Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma. - Wikidata - awgldk - TriplyDB

Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma.

Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma.

http://www.wikidata.org/entity/Q36162690

about

Inhibiting heat shock factor 1 in human cancer cells with a potent RNA aptamer Hsp90: A New Player in DNA Repair?Ganetespib: research and clinical development New molecular targets in mantle cell lymphoma New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers Heat shock proteins and heat shock factor 1 in carcinogenesis and tumor development: an update New strategies in the treatment of multiple myeloma.The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms Schwann cell autophagy induced by SAHA, 17-AAG, or clonazepam can reduce bortezomib-induced peripheral neuropathy Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic Molecular targeted approaches in mantle cell lymphoma.Heteroclitic XBP1 peptides evoke tumor-specific memory cytotoxic T lymphocytes against breast cancer, colon cancer, and pancreatic cancer cells.Hsp90 molecular chaperone inhibitors: are we there yet?A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma Tipifarnib and tanespimycin show synergic proapoptotic activity in U937 cells Tumor-intrinsic and tumor-extrinsic factors impacting hsp90- targeted therapy.Multiple Myeloma: Treatment is Getting Individualized Effects of treatment with an Hsp90 inhibitor in tumors based on 15 phase II clinical trials.Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia.Phase I study of tanespimycin in combination with bortezomib in patients with advanced solid malignancies.Unfolded protein response in cancer: the physician's perspective Bortezomib combination therapy in multiple myeloma.Emerging biological insights and novel treatment strategies in multiple myeloma.Perspectives in the treatment of multiple myeloma.Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib.

P2860

Q21132046-E7CA9E00-1CD1-43C6-9D84-1B0808477A0E Q26778944-4D395940-AFFE-40E6-9077-FA2F9A386B07 Q26798645-39B7E15B-B0D8-45FC-8B17-3FE229ADFCAE Q26821766-C2938B8A-00AF-4FAA-A38E-43F65732ABE9 Q27004421-68EB4C49-9CF2-4F51-A694-F2D3018C3ABF Q27022514-03E3B715-D12A-4036-902D-B2D32D31A7DB Q28272905-24C38A7C-C917-4F0E-8962-1393BEF00294 Q33958520-DEC8A58B-6E40-4D75-9CEB-46B72C9370EB Q34165045-7CA0DCDB-195E-40A4-BF34-D51007AC9298 Q34344053-F193FD2D-A288-446D-9DE3-1E5805084C89 Q34817365-9D7EE497-BEC4-4505-90E6-B9DFEDA456BD Q35127368-60E9C94B-D927-45CB-BA01-EB0677303282 Q35166674-08757D5B-DC52-44CA-BC2E-DE097F19D244 Q35655105-03395194-C5DD-4B95-ACC7-BDCC7DC8F80C Q35691439-EB7E8C0C-2294-4825-9FEF-B2D0A850C2EA Q35754391-EBDD129D-70BA-4171-80CB-FF2142E408B4 Q36465517-29DA8C17-9D12-4C89-AA6F-D03E92FF1B1D Q36522964-6B16C011-5AA5-4672-8115-4A3D6E2DD572 Q37204596-A925F300-C510-4E91-B8B6-841C4BF67121 Q37386171-B5ECF978-15AD-496B-9D04-FE0B66A33BA3 Q37594553-7D7FEA31-D2B1-4651-B975-B9D68C84C1CF Q37846249-5694753D-60AD-49A7-9FEA-B1A27033329C Q38021041-67046B54-3CF4-4525-B53B-0DDDB79FFEA4 Q38037600-0EC109DA-C7BD-49C8-B6CA-98EAAF64CAD8 Q38108391-E081364A-252F-4B46-A873-CD92D672DF47 Q42138375-98E83F46-7986-4520-95DE-C54729753703

P2860

Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma.

http://www.wikidata.org/entity/Q36162690

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Tanespimycin with bortezomib: ...... atients with multiple myeloma.

@ast

Tanespimycin with bortezomib: ...... atients with multiple myeloma.

@en

type

label

Tanespimycin with bortezomib: ...... atients with multiple myeloma.

@ast

Tanespimycin with bortezomib: ...... atients with multiple myeloma.

@en

prefLabel

Tanespimycin with bortezomib: ...... atients with multiple myeloma.

@ast

Tanespimycin with bortezomib: ...... atients with multiple myeloma.

@en

P1433

Q36162690-BF121272-FB7E-4BF7-9DF9-6DDCCB69334B

P1476

Q36162690-421A7F46-A731-4B2D-A2D4-7C051E357325

P2093

Q36162690-18AC17B5-F8D0-440E-A9CB-0238AF7878B4

Q36162690-2D3E3DDD-92A7-41C3-9B2A-68CDB37C06A7

Q36162690-72113753-A8DB-46AB-8EEE-56DA90497475

Q36162690-7BEF4DBF-3002-43DD-A249-6A509C8384D5

Q36162690-9D30EA7A-6019-4D4B-A6BF-44E9C3E05065

Q36162690-C6F56C1C-A197-4A80-A19E-E2185374AA11

Q36162690-D0FFAFFE-3838-4AE7-A776-69DE8FFD0C52

Q36162690-F2300D2C-E92C-4BE4-B038-9E879FF1649B

P2860

Q36162690-086C2E15-8F91-4080-9B8D-E4D045DDCBDC

Q36162690-0A11167C-D8FB-4DC6-AAA5-E188845DD83C

Q36162690-0D215EE1-6A92-433E-9AA4-97995E4BBC84

Q36162690-1414093B-74EC-4D99-8C45-CEE670089530

Q36162690-19A4015E-C683-404C-8856-037359E3FF8D

Q36162690-1FB0F54E-4CD3-404B-A480-D2A10735F58A

Q36162690-21B08D7C-1D72-48DD-BB5A-2598531A41F9

Q36162690-4F691F27-37E6-4EF6-AAEC-51FC7A506845

Q36162690-53642F59-F7E2-4705-9490-E0F3BEE846F7

Q36162690-5695ED41-8611-4657-9AEA-4E03F48C7EDE

P304

Q36162690-D3477E59-ACE0-4558-BEB0-BF3D6A13C290

P31

Q36162690-43517468-9603-4B34-BE67-C79CE8FDFC49

P356

Q36162690-169EC2F5-354E-47CD-B550-FF16BC844BF0

P407

Q36162690-61C0B13C-7BE6-4550-8586-6110DF065C6F

P433

Q36162690-5E1D5117-AF6F-4C88-AE47-CCD3A3DC4B71

P478

Q36162690-554AA881-FE09-4CAC-A28A-EBEF2CFBF2D6

P50

Q36162690-4E18B890-29B3-4EFA-B021-7DB4E7A78BE3

P577

Q36162690-7F54F5BD-322E-4594-8B61-74AC85032030

P5875

Q36162690-F846A788-8C9D-41D3-B2B5-FB9E7CD892F1

P698

Q36162690-56179E50-757C-4683-8985-EB1C2730679E

P932

Q36162690-20F4481E-04A7-4D27-A0AF-88310F6E932F

P356

J.1365-2141.2010.08264.X

P1433

British Journal of Haematology

P1476

Tanespimycin with bortezomib: ...... atients with multiple myeloma.

@en

P2093

Ashraf Z Badros

http://www.w3.org/2001/XMLSchema#string

David Berman

http://www.w3.org/2001/XMLSchema#string

Jeffrey L Wolf

http://www.w3.org/2001/XMLSchema#string

Kenneth C Anderson

http://www.w3.org/2001/XMLSchema#string

Marianne Messina

http://www.w3.org/2001/XMLSchema#string

Paul G Richardson

http://www.w3.org/2001/XMLSchema#string

Stefano Tarantolo

http://www.w3.org/2001/XMLSchema#string

Sundar Jagannath

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2008

Heat shock proteins and protection of the nervous system

HSP90 and the chaperoning of cancer

A phase 2 study of bortezomib in relapsed, refractory myeloma.

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.

Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies.

Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.

Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers.

Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.

P304

428-437

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2141.2010.08264.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

150

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-07-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45147485

http://www.w3.org/2001/XMLSchema#string

P698

20618338

http://www.w3.org/2001/XMLSchema#string

P932

3418598

http://www.w3.org/2001/XMLSchema#string